Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Codiak BioSciences, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 26 Jan 2023, 15:15.
Douglas E. Williams - 24 Jan 2023 Form 4 Insider Report for Codiak BioSciences, Inc.
- Reporting relationship
- President & CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jan 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Jan 2023, 15:15:23 UTC
- Prior SEC filing
- 23 Jan 2023
- Next SEC filing
- 30 Mar 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Yalonda Howze, Attorney-in-Fact for Douglas E. Williams
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Codiak BioSciences, Inc. on 26 Jan 2023.
Change
- Previous filing in this sequence was filed on 23 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CDAKQ
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +465,000
- Change %
- Price
- $0.000000
- Shares after
- 465,000
- Date
- 24 Jan 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 465,000
- Exercise price
- $0.7400
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
25% of this option shall vest and become exercisable on January 24, 2024, with the remainder vesting in 12 equal quarterly installments thereafter.